COVID19 Update: For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patients protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine are available for routine office visits. More Information-PLEASE CLICK HERE

Dr. Alex Spira quoted in announcement from Mirati Theraputics: Progress Of Lead Programs And Updated Positive Clinical Trial Results For Immuno-Oncology Combination Trials

Virginia Cancer Specialists Practice Blog

April 26, 2018
Virginia Cancer Specialists » VCS Practice News » Physicians » VCS Practice News » Alex Spira MD PhD FACP » Dr. Alex Spira quoted in announcement from Mirati Theraputics: Progress Of Lead Programs And Updated Positive Clinical Trial Results For Immuno-Oncology Combination Trials

Mirati Therapeutics Announces Progress Of Lead Programs And Provides Updated Positive Clinical Trial Results For Immuno-Oncology Combination Trials

  1. Six Partial Responses achieved to date in first 23 evaluable patients receiving the combination of sitravatinib and nivolumab for the treatment of checkpoint inhibitor refractory non-small cell lung cancer
  2. Tumor reductions observed in 19 of 23 evaluable patients
  3. 45 patients have been enrolled in the Phase 2 study, with plans to present more mature data at an oncology conference later this year
  4. Three Partial Responses achieved in the first 23 evaluable patients receiving the combination of mocetinostat and durvalumab for the treatment of checkpoint refractory non-small cell lung cancer
  5. To date, the combination has been well-tolerated and most adverse events (AEs) reported by investigators were Grade 1 or 2.

“The responses and duration of treatment seen with the combination of sitravatinib and a checkpoint inhibitor are very promising, notably because these patients had relapsed following prior checkpoint inhibitor therapy,” said Alexander Spira, M.D., Ph.D., Director of the Virginia Cancer Specialists Research Institute. “The trial is enrolling well, and we have been pleased with the favorable tolerability of the combination.”

See Full Press Release Here

 


Previous

1 of 1

Next